tucatinib,trastuzumab,trastuzumab deruxtecan,ruxolitinib
seagen,daiichi sankyo,astrazeneca,incyte,novartis
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'tucatinib']
a masterclass by dr. summarizing the landscape of her2+ treatments in mcrc with t-dxd and tucatinib/trastuzumab seeming to rise to the top #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.